Targeting cancer's sweet spot: UGP2 as a therapeutic vulnerability.
UDP-glucose
UGP2
YAP
cancer metabolism
glycosylation
Journal
Molecular & cellular oncology
ISSN: 2372-3556
Titre abrégé: Mol Cell Oncol
Pays: United States
ID NLM: 101642411
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
14
4
2022
pubmed:
15
4
2022
medline:
15
4
2022
Statut:
epublish
Résumé
Understanding the mechanisms governing metabolic reprogramming that underlie potential vulnerabilities in cancer cells is key to developing novel therapeutic strategies. The catalytic enzyme UDP-glucose pyrophosphorylase 2 (UGP2) drives the production of UDP-glucose. Our recent work demonstrated the crucial role of UGP2 in cancer growth and its regulation of cellular metabolic processes.
Identifiants
pubmed: 35419477
doi: 10.1080/23723556.2021.1990676
pii: 1990676
pmc: PMC8997258
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1990676Subventions
Organisme : NCI NIH HHS
ID : R00 CA226363
Pays : United States
Informations de copyright
© 2021 Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
A.L.W. received research funding from Oncogenuity, Inc. for an unrelated project.
Références
J Cell Biochem. 2019 Aug;120(8):12489-12499
pubmed: 30816613
Sci Rep. 2015 Apr 10;5:9618
pubmed: 25860585
Proteins. 2017 Aug;85(8):1529-1549
pubmed: 28486782
Planta. 2001 Mar;212(4):598-605
pubmed: 11525517
Biochim Biophys Acta. 2014 Nov;1843(11):2592-602
pubmed: 24983772
Int J Mol Sci. 2020 Mar 16;21(6):
pubmed: 32188137
Anal Biochem. 1982 Feb;120(1):181-8
pubmed: 6178310
Acta Neuropathol. 2020 Mar;139(3):415-442
pubmed: 31820119
Proc Natl Acad Sci U S A. 2021 Aug 3;118(31):
pubmed: 34330832
Cell. 2002 Oct 4;111(1):17-28
pubmed: 12372297